https://scholars.lib.ntu.edu.tw/handle/123456789/563570
標題: | New international association for the study of lung cancer (Iaslc) pathology committee grading system for the prognostic outcome of advanced lung adenocarcinoma | 作者: | Weng C.-F. Huang C.-J. Huang S.-H. Wu M.-H. Tseng A.H. Sung Y.-C. Lee H.H.-C. THAI-YEN LING |
關鍵字: | EGFR mutation; Histology; Late stage; Lung adenocarcinoma; Sex; Smoker; Subtype | 公開日期: | 2020 | 卷: | 12 | 期: | 11 | 起(迄)頁: | 1-14 | 來源出版物: | Cancers | 摘要: | The impact of the new International Association for the Study of Lung Cancer pathology committee grading system for advanced lung adenocarcinoma (LADC) on survival is unclear, especially in Asian populations. In this study, we reviewed the prognostic outcomes of patients with late-stage disease according to the new grading system. We reviewed 136 LADC cases who underwent a small biopsy from 2007 to 2018. Tumors were classified according to the new grading system for LADC. Baseline characteristics (age, sex, smoking status, body mass index, and driver gene mutations) were analyzed. Kaplan–Meier and Cox regression analyses were used to determine correlations with the new grading system and prognosis. Patients with poorly differentiated adenocarcinoma were significantly correlated with a poor progression-free survival (PFS) (p = 0.013) but not overall survival (OS) (p = 0.154). Subgroup analysis showed that wild-type EGFR patients with poorly differentiated adenocarcinoma treated with chemotherapy had significantly worse PFS (p = 0.011). There was no significant difference in survival among the patients with epidermal growth factor receptor mutations who were treated with tyrosine kinase inhibitors. Patients aged >70 years and those with a BMI ? 25 kg/m2 and wild-type patients had significantly worse OS in both univariate (HR = 1.822, p = 0.006; HR = 2.250, p = 0.004; HR = 1.537, p = 0.046, respectively) and multivariate analyses (HR = 1.984, p = 0.002; HR = 2.383, p = 0.002; HR = 1.632, p = 0.028, respectively). Despite therapy, patients with poorly differentiated tumors still fared worse than those with better differentiated tumors. No differences were found among the EGFR mutations treated with TKI. Our findings highlight that the therapeutic regimen should be adjusted for EGFR Wild-type patients with poorly differentiated adenocarcinoma treated with chemotherapy to provide better outcomes. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/563570 | ISSN: | 20726694 | DOI: | 10.3390/cancers12113426 | SDG/關鍵字: | afatinib; crizotinib; epidermal growth factor receptor; erlotinib; gefitinib; gemcitabine; pemetrexed; vinorelbine tartrate; adult; advanced cancer; aged; Article; cancer classification; cancer grading; cancer prognosis; carcinogenesis; EGFR gene; female; gene; gene mutation; human; lung adenocarcinoma; major clinical study; male; overall survival; progression free survival; survival analysis |
顯示於: | 藥理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。